Skip to main content
OpenTrials
Completed

NCT Number: NCT04709016

Drug Use During Sex and Its Impact on Taking PrEP (Pre-Exposure Prophylaxis) : CONSUME

This is a cross-sectional, single-center observational study conducted from October 2020 to March 2021 in Ile de France at the infectious disease of CHU Bichat (PrEP and CeGIDD(Free Center for Information, Screening and Diagnosis of Infections by Human Immunodeficiency Viruses, Viral Hepatitis and Sexually Transmitted Infections) consultation). It concerns adult subjects of male or transgender sex, of MSM (men having sex with men) or bi-sexual orientation. The data are collected by self-questionnaire evaluating the consumption of Chemsex (drug use in a sexual context) over the last 12 months, the existence or not of addiction treatment, the history of STIs (sexually transmitted infections) and adherence to PrEP (for subjects taking PrEP) during the last sexual intercourse (ANRS questionnaire, used in the PREVENIR study).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Drug Dependence Behavior Chemically-Induced Disorders Chemsex Mental Disorders Sexual Behavior Substance-Related Disorders

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

SMIT - Hôpital Bichat

Paris, 75018, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age> 18
  • male or transgender
  • MSM or bi-sexual orientation
  • adult consultant at Bichat Hospital (CeGIDD or PrEP consultation)
  • adult with a Smartphone (online self-questionnaire)

Exclusion criteria

  • For the group "taking PrEP": adult taking PrEP for less than 3 months
  • Refusal of participation

Treatment and study plan

self-questionnaire

Behavioral

self-questionnaire assessing Chemsex's (drug use in a sexual context) consumption over the last 12 months

Primary outcomes

  1. compare in an MSM and transgender population, the use of Chemsex depending on whether or not PrEP is taken

    Time frame: inclusion

Secondary outcomes

  1. Reported adherence to PrEP

    Time frame: inclusion

  2. The existence or not of psychological comorbidity and the existence of addictological care

    Time frame: inclusion

  3. The number of sexually transmitted infections at inclusion

    Time frame: inclusion

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

The Use of Chemsex (Drug Use in a Sexual Context) Among MSM (Men Who Have Sex With Men) and Transgender People in France, Whether or Not Taking PrEP, and Its Impact on PrEP Adherence

Acronym: CONSUME

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jan 14, 2021
Registry last updated
Aug 30, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.